Literature DB >> 23122637

Role of high-resolution ultrasound and PET/CT imaging for preoperative characterization of sentinel lymph nodes in cutaneous melanoma.

Torsten Hinz1, Harald Voth, Hojjat Ahmadzadehfar, Tobias Hoeller, Joerg Wenzel, Thomas Bieber, Monika-H Schmid-Wendtner.   

Abstract

The purpose of our study was the comparison of high-resolution ultrasound (HRUS) and positron emission tomography combined with computerised tomography (PET/CT) in the preoperative characterization and identification of subclinical nodal metastases focusing on sentinel lymph nodes (SLN) in melanoma patients. Patients with cutaneous melanoma (CM) who received sentinel lymph node biopsy at the Department of Dermatology and Allergy, University of Bonn, between January 2009 and January 2011 had been evaluated with a retrospective computer-aided search concerning preoperative staging procedures. A combination of PET/CT and HRUS had been performed preoperatively in 20 of 123 patients. A total of 59 SLNs had been removed in those 20 patients followed by histopathologic examination. HRUS correctly identified two of 17 positive SLNs whereas PET/CT imaging identified none. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of HRUS were 11.8 % (95 % confidence interval [CI] = 3.3-34.3), 100 % (95 % CI = 91.6-100.0), 100.0 % (95 % CI = 34.2-100.0), and 73.7 % (95 % CI = 61.0-83.3), respectively. On the basis of this limited study cohort, HRUS had a better value than PET/CT in preoperative identification of positive SLNs, suggesting a possible diagnostic superiority of HRUS in general characterization of peripheral nodal disease in CM.
Copyright © 2013 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23122637     DOI: 10.1016/j.ultrasmedbio.2012.08.024

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  6 in total

Review 1.  A review of sentinel lymph node biopsy for thin melanoma.

Authors:  K M Joyce; N M McInerney; C W Joyce; D M Jones; A J Hussey; P Donnellan; M J Kerin; J L Kelly; P J Regan
Journal:  Ir J Med Sci       Date:  2014-11-01       Impact factor: 1.568

2.  Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?

Authors:  Benedikt Michael Schaarschmidt; Johannes Grueneisen; Vanessa Stebner; Joachim Klode; Ingo Stoffels; Lale Umutlu; Dirk Schadendorf; Philipp Heusch; Gerald Antoch; Thorsten Dirk Pöppel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-06       Impact factor: 9.236

3.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

Authors:  Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01

4.  Gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol.

Authors:  Charlotte M C Oude Ophuis; Lisa B Koppert; Cécile de Monyé; Carolien H M van Deurzen; Senada Koljenović; Alexander C J van Akkooi; Cornelis Verhoef; Dirk J Grünhagen
Journal:  BMC Cancer       Date:  2017-04-12       Impact factor: 4.430

Review 5.  PET-CT in Clinical Adult Oncology-VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors.

Authors:  Gabriel C Fine; Matthew F Covington; Bhasker R Koppula; Ahmed Ebada Salem; Richard H Wiggins; John M Hoffman; Kathryn A Morton
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

6.  Canadian Melanoma Conference Recommendations on High-Risk Melanoma Surveillance: A Report from the 14th Annual Canadian Melanoma Conference; Banff, Alberta; 20-22 February 2020.

Authors:  Christina W Lee; J Gregory McKinnon; Noelle Davis
Journal:  Curr Oncol       Date:  2021-05-27       Impact factor: 3.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.